Skip to content
value.today

Amalgam Rx, Inc.

🇺🇸 Wilmington, Delaware, USAHealth CareFounded 2016
Total raised
$26 M
3 rounds on record
Latest round
$8 M
Aug 2025
First round on record
Jun 2017
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Amalgam Rx, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2025$8 MNo. 3$2 to $10 million

Amalgam Rx, Inc.: Raise no. 3, Aug 2025

Investors in this round

28 investors had bought by the notice of Aug 15, 2025: 28 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $8 M offered
Smallest investment taken
no minimum stated
What was sold
equity, debt
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$616,250
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Ryan A. Sysko · Executive Officer, Director
  • Jeffrey P. Courtney · Director
  • Sonny P. Vu · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • ERG SECURITIES (US) LLC (CRD 121057) · Norwalk, ConnecticutSold in NY

Remarks in the notice

  • On fees: “In connection with the offering, a portion of the sales commission will be paid to the broker in the form of a warrant to purchase preferred stock of the issuer.”
  • On the amounts: “A portion of the offering amount represents loan proceeds, which are convertible into equity securities of the issuer pursuant to the terms and conditions of a loan and security agreement.”

Signed by Ryan A. Sysko, Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 15, 2025. Read the notice at the SEC.

equity, debtSEC
Dec 2022$17 MNo. 2$10 to $50 million

Amalgam Rx, Inc.: Raise no. 2, Dec 2022

Investors in this round

62 investors had bought by the notice of Jan 3, 2023: 62 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$17 M of $45 M offered; $28 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Ryan Sysko · Executive Officer, Director
  • Jeffrey Courtney · Director
  • Sonny Vu · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Ryan A. Sysko, Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 3, 2023. Read the notice at the SEC.

equitySEC
Jun 2017$1 MNo. 1Under $2 million

Amalgam Rx, Inc.: Raise no. 1, Jun 2017

Investors in this round

27 investors had bought by the notice of May 3, 2019: 27 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $2 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
$9,388
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks finders' fees as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Ryan A Sysko · Executive Officer, Director
  • Sarwar A Islam · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Steven Sarigianis (CRD 1526658) · Baltimore, MarylandSold in MD, NJ

Remarks in the notice

  • On fees: “Estimate is based on the issuer's good faith valuation of the finders' fee, which was paid other than in cash.”

Signed by Ryan A. Sysko, President and CEO. Source: SEC Form D, newest notice filed May 3, 2019. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Amalgam Rx, Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2025).

    SEC Form D · Aug 2025

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Aug 2025

That is all the official record says: Amalgam Rx, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Amalgam Rx, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 62 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Amalgam Rx, Inc.
NameRoleNamed in
Ryan A. SyskoExecutive officerAug 2025
Ryan SyskoExecutive officerJan 2023
Ryan A SyskoExecutive officerMay 2019
Jeffrey P. CourtneyDirectorAug 2025
Ryan A. SyskoDirectorAug 2025
Sonny P. VuDirectorAug 2025
Jeffrey CourtneyDirectorJan 2023
Ryan SyskoDirectorJan 2023
Sonny VuDirectorJan 2023
Ryan A SyskoDirectorMay 2019
Sarwar A IslamDirectorMay 2019